PL2744831T3 - Białko fuzyjne transferryna-tumstatyna oraz sposoby jego wytwarzania i stosowania - Google Patents

Białko fuzyjne transferryna-tumstatyna oraz sposoby jego wytwarzania i stosowania

Info

Publication number
PL2744831T3
PL2744831T3 PL12824616T PL12824616T PL2744831T3 PL 2744831 T3 PL2744831 T3 PL 2744831T3 PL 12824616 T PL12824616 T PL 12824616T PL 12824616 T PL12824616 T PL 12824616T PL 2744831 T3 PL2744831 T3 PL 2744831T3
Authority
PL
Poland
Prior art keywords
transferrin
producing
methods
same
fusion protein
Prior art date
Application number
PL12824616T
Other languages
English (en)
Polish (pl)
Inventor
Uday B. Kompella
Robert I. SCHEINMAN
Puneet Tyagi
Original Assignee
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Colorado, A Body Corporate filed Critical The Regents Of The University Of Colorado, A Body Corporate
Publication of PL2744831T3 publication Critical patent/PL2744831T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL12824616T 2011-08-17 2012-08-15 Białko fuzyjne transferryna-tumstatyna oraz sposoby jego wytwarzania i stosowania PL2744831T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524508P 2011-08-17 2011-08-17
EP12824616.2A EP2744831B1 (en) 2011-08-17 2012-08-15 Transferrin-tumstatin fusion protein and methods for producing and using the same
PCT/US2012/051013 WO2013025846A2 (en) 2011-08-17 2012-08-15 Transferrin-tumstatin fusion protein and methods for producing and using the same

Publications (1)

Publication Number Publication Date
PL2744831T3 true PL2744831T3 (pl) 2018-05-30

Family

ID=47715692

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12824616T PL2744831T3 (pl) 2011-08-17 2012-08-15 Białko fuzyjne transferryna-tumstatyna oraz sposoby jego wytwarzania i stosowania

Country Status (15)

Country Link
US (1) US9290562B2 (enExample)
EP (1) EP2744831B1 (enExample)
JP (1) JP6073888B2 (enExample)
CN (2) CN110105453A (enExample)
AU (1) AU2012296588B2 (enExample)
BR (1) BR112014008680A2 (enExample)
CA (1) CA2849015C (enExample)
DK (1) DK2744831T3 (enExample)
ES (1) ES2659161T3 (enExample)
NO (1) NO2820418T3 (enExample)
PL (1) PL2744831T3 (enExample)
PT (1) PT2744831T (enExample)
SI (1) SI2744831T1 (enExample)
TR (1) TR201802686T4 (enExample)
WO (1) WO2013025846A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2995626B1 (en) * 2013-05-06 2018-07-11 China Pharmaceutical University Bifunctional fusion proteins to inhibit angiogenesis in tumour microenvironment and to activate adaptive immune responses and the genes and uses thereof
EP3010525A1 (en) * 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
US11058750B2 (en) * 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
KR101818151B1 (ko) 2016-03-25 2018-01-16 한국과학기술원 트렌스페린을 포함하는 허혈성망막병증 예방 및 치료용 조성물
CN109053899B (zh) * 2017-12-22 2021-11-16 湖南远泰生物技术有限公司 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US20050192242A1 (en) 1995-10-11 2005-09-01 Neal Zane C. Therapeutic fusion protein transgenes
KR100682666B1 (ko) * 1998-06-17 2007-02-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 항혈관형성 단백질 및 이들을 사용하는 방법
EP1244701A1 (en) 1999-12-23 2002-10-02 Human Genome Sciences, Inc. Transferrin polynucleotides, polypeptides, and antibodies
JP2005508623A (ja) 2001-08-30 2005-04-07 バイオレクシス ファーマシューティカル コーポレイション 改変されたトランスフェリン融合タンパク質
US8129504B2 (en) * 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003066824A2 (en) * 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
EP1670428A4 (en) 2003-10-10 2008-03-12 Univ Southern California HYBRID PROTEINS G-CSF-TRANSFERRIN
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
EP1812030A4 (en) * 2004-10-14 2009-01-14 Sopherion Therapeutics Inc ANTI-ANGIOGENIC PEPTIDES AND METHODS OF USE THEREOF
WO2006049983A2 (en) 2004-10-27 2006-05-11 Biorexis Pharmaceutical Corporation Peptide yy modified transferrin fusion proteins
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
AU2007211846B2 (en) 2006-02-03 2013-05-23 The University Of Sydney A method of modulating cellular activity and agents for use therein
CN101070349B (zh) * 2007-05-22 2010-10-13 山西康宝生物制品股份有限公司 具有选择性杀伤肿瘤新生血管内皮细胞作用的融合蛋白与应用
CN101092452A (zh) * 2007-05-23 2007-12-26 哈尔滨医科大学 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法
WO2009086132A2 (en) * 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs

Also Published As

Publication number Publication date
AU2012296588A1 (en) 2014-04-03
CA2849015C (en) 2017-08-08
BR112014008680A2 (pt) 2017-06-13
JP2014526890A (ja) 2014-10-09
CN103998470A (zh) 2014-08-20
EP2744831A2 (en) 2014-06-25
SI2744831T1 (en) 2018-04-30
DK2744831T3 (en) 2018-03-05
US9290562B2 (en) 2016-03-22
WO2013025846A2 (en) 2013-02-21
AU2012296588B2 (en) 2017-07-27
CN110105453A (zh) 2019-08-09
WO2013025846A3 (en) 2013-05-02
EP2744831B1 (en) 2017-12-06
CA2849015A1 (en) 2013-02-21
PT2744831T (pt) 2018-03-05
JP6073888B2 (ja) 2017-02-01
TR201802686T4 (tr) 2018-03-21
ES2659161T3 (es) 2018-03-14
NO2820418T3 (enExample) 2018-05-05
US20140179612A1 (en) 2014-06-26
EP2744831A4 (en) 2015-03-11

Similar Documents

Publication Publication Date Title
PT2697187T (pt) Olefinas e métodos para produção das mesmas
IL240898A0 (en) Antibodies against a5c and methods of using the antibodies
EP2699719A4 (en) TUBULAR STRUCTURE AND MANUFACTURING METHOD THEREFOR
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
IL233757A0 (en) Anti '1m e-gi antibodies and methods of using them
SI3321287T1 (sl) Fuzijski proteini in kombinirana cepiva
IL232743A0 (en) anticancer fusion protein
ZA201400562B (en) Axmi205 variant proteins and methods for their use
SG10201604332XA (en) Membrane and method for making the same
SG10202100341XA (en) Npp1 fusion proteins
SMT201700300T1 (it) "proteina di fusione anticancro
ZA201405460B (en) Anticancer fusion protein
EP2698386B8 (en) Fusion protein
EP2657337A4 (en) FUSION PROTEIN
ZA201308597B (en) Anticancer fusion protein
EP2718432A4 (en) NUCLEASE FUSION PROTEIN AND USES THEREOF
PT2744831T (pt) Proteína de fusão de transferrina-tumstatina e métodos para a produzir e utilizar
ZA201207425B (en) Fusion protein
SG2014008601A (en) Method for producing clean packageing material and the clean packageing material
GB201114701D0 (en) Fusion proteins
GB201107189D0 (en) Fusion proteins
AU2011905145A0 (en) Fusion Protein
AU2011902431A0 (en) Fusion Proteins and Use Thereof
GB201007955D0 (en) Somatosatin fusion proteins